Metabolic activation of the antitumor drug 5-(aziridin-1-yl)-2,4- dinitrobenzamide (CB1954) by NO synthases

Chemical Research in Toxicology

Volumn 21, Issue 4, 2008, Pages 836-843

  Chandor, Alexia ^a   Dijols, Sylvie ^a   Ramassamy, Booma ^a   Frapart, Yves ^a   Mansuy, Daniel ^a   Stuehr, Dennis ^b   Helsby, Nuala ^c   Boucher, Jean Luc ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b LERNER RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

5 (1 AZIRIDINYL) 2,4 DINITROBENZAMIDE; ANTINEOPLASTIC AGENT; ARGININE; CALMODULIN; CARBON MONOXIDE; DIPHENYLIODONIUM SALT; FREE RADICAL; HYDROXYLAMINE; IMIDAZOLE; LIGAND; NITRIC OXIDE SYNTHASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE;

ARTICLE; CATALYSIS; DRUG ACCUMULATION; DRUG ACTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; METABOLIC ACTIVATION; NERVE CELL;

ANIMALS; ANTINEOPLASTIC AGENTS; AZIRIDINES; BIOTRANSFORMATION; CATTLE; MICE; NITRIC OXIDE SYNTHASE; RATS; RECOMBINANT PROTEINS;

EID: 43149092479     PISSN: 0893228X     EISSN: None     Source Type: Journal    
DOI: 10.1021/tx7004234     Document Type: Article

References (54)

1. Kerwin, J. F., Lancaster, J. R., and Feldman, P. L. (1995) Nitric oxide: A new paradigm for second messengers. J. Med. Chem. 38, 4343-4362.
2. Pfeiffer, S., Mayer, B., and Hemmens, B. (1999) Nitric oxide. Chemical puzzles posed by a biological messenger. Angew. Chem., Int. Ed. 38, 1714-1731.
3. Alderton, W. K., Cooper, C. E., and Knowles, R. G. (2001) Nitric oxide synthases: Structure, function and inhibition. Biochem. J. 357, 593-615.
4. Masters, B. S. S., McMillan, K., Sheta, E. A., Nishimura, J. S., Roman, L. J., and Martasek, P. (1996) Neuronal nitric oxide synthase, a modular enzyme formed by convergent evolution: Structure studies of a cysteine thiolate-liganded heme protein that hydroxylates L-arginine to produce NO as a cellular signal. FASEB J. 10, 552-558.
5. Li, H., and Poulos, T. L. (2005) Structure-function studies on nitric oxide synthases. J. Inorg. Biochem. 99, 293-305.
6. 2+/Calmodulin-dependent cytochrome c reductase activity of brain nitric oxide synthase. J. Biol. Chem. 267, 11374-11378.
7. Abu-Soud, H. M., Yoho, L. L., and Stuehr, D. J. (1994) Calmodulin controls neuronal nitric oxide synthase by a dual mechanism. J. Biol. Chem. 269, 32047-32050.
8. Bredt, D. S., Hwang, P. M., Glatt, C. E., Lowenstein, C., Reed, R. R., and Snyder, S. H. (1991) Cloned and expressed nitric oxide synthase structurally resembles cytochrome P-450 reductase. Nature 351, 714-718.
9. Miyajima, M., Sagami, I., Daff, S., Migita, C. T., and Shimizu, T. (2000) Azo reduction of Methyl Red by neuronal nitric oxide synthase. The importance of FMN in catalysis. Biochem. Biophys. Res. Commun. 275, 752-758.
10. Väsquez-Vivar, J., Martäsek, P., Hogg, N., Masters, B. S. S., Pritchard, K. A., and Kalyanaraman, B. (1997) Endothelial nitric oxide synthase-dependent superoxide generation from adriamycin. Biochemistry 36, 11293-11297.
11. Kumagai, Y., Nakajima, H., Midorikawa, K., Homma-Takeda, S., and Shimojo, N. (1998) Inhibition of nitric oxide formation by neuronal nitric oxide synthase by quinones: Nitric oxide synthase as a quinone reductase. Chem. Res. Toxicol. 11, 608-613.
12. Garner, A. P., Paine, M. J. I., Rodriguez-Crespo, I., Chinje, E. C., Ortiz de Montellano, P., Stratford, I. J., Tew, D. G., and Wolf, C. R. (1999) Nitric oxide synthases catalyze the activation of redox cycling and bioreductive anticancer agents. Cancer Res. 59, 1929-1934.
13. Jiang, H. B., Ichikawa, W., Furukawa, A., Tomita, S., and Ichikawa, Y. (2000) Reductive activation of mitomycin C by neuronal nitric oxide synthase. Biochem. Pharmacol. 60, 571-579.
14. Matsuda, H., Kimura, S., and Iyanagi, T. (2000) One electron reduction of quinones by the neuronal nitric oxide synthase reductase domain. Biochim. Biophys. Acta 1459, 106-116.
15. Miller, R. T. (2002) Dinitrobenzene-mediated production of peroxynitrite by neuronal nitric oxide synthase. Chem. Res. Toxicol. 15, 927-934.
16. Huie, R. E., and Padmaja, S. (1993) The reaction of NO with superoxide. Free Radical Res. Commun. 18, 195-199.
17. Ask, K., Dijols, S., Giroud, C., Casse, L., Frapart, Y., Sari, M.-A., Kim, K.-S., Stuehr, D. J., Mansuy, D., Camus, P., and Boucher, J.-L. (2003) Reduction of nilutamide by NO synthases: Implications for the adverse effects of this nitroaromatic antiandrogen drug. Chem. Res. Toxicol. 16, 1547-1554.
18. Gram, T. E. (1997) Chemically reactive intermediates and pulmonary xenobiotic toxicity. Pharmacol. Rev. 49, 297-341.
19. Gomez, J. L., Dupont, A., Cusan, L., Tremblay, M., and Labrie, F. (1992) Simultaneous liver and lung toxicity related to the nonsteroidal antiandrogen nilutamide (Anandron). A case report. Am. J. Med. 92, 563-566.
20. Jarman, M., Melzack, D. H., and Ross, W. C. J. (1976) The metabolism of the anti-tumor agent 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954). Biochem. Pharmacol. 25, 2475-2478.
21. Bridgewater, J. A., Springer, C. J., Knox, R. J., Minton, N. P., Michael, N. P., and Collins, M. K. (1995) Expression of the bacterial nitroreductase enzyme in mammalian cells renders them selectively sensitive to killing by the prodrug CB1954. Eur. J. Cancer 31A, 2362-2370.
22. Knox, R. J., Friedlos, F., Jarman, M., and Roberts, J. J. (1988) A new cytotoxic, DNA interstrand crosslinking agent, 5-(aziridin-1-yl)-4- hydroxylamino-2-nitrobenzamide, is formed from 5-(aziridin-1-yl)-2,4- dinitrobenzamide (CB1954) by a nitroreductase enzyme in Walker carcinoma cells. Biochem. Pharmacol. 37, 4661-4669.
23. Knox, R. J., Friedlos, F., Biggs, P. J., Flitter, W. D., Gaskell, M., Goddard, P., Davies, L., and Jarman, M. (1993) Identification, synthesis and properties of 5-(aziridin-1-yl)-2-nitro-4-nitroso benzamide, a novel DNA crosslinking agent derived from CB1954. Biochem. Pharmacol. 46, 797-803.
24. Knox, R. J., Friedlos, F., Marchbank, T., and Roberts, J. J. (1991) Bioactivation of CB1954: Reaction of the active 4-hydroxylamino derivative with thioesters to form the ultimate DNA-DNA interstrand crosslinking species. Biochem. Pharmacol. 42, 1691-1697.
25. Helsby, N. A., Ferry, D. M., Patterson, A. V., Pullen, S. M., and Wilson, W. R. (2004) 2-Amino metabolites are key mediators of CB1954 and SN23862 bystander effects in nitroreductase GDEPT. Br. J. Cancer 90, 1084-1092.
26. Denny, W. A. (2004) Tumor-activated prodrugs: A new approach to cancer therapy. Cancer Invest. 22, 604-619.
27. Robson, T., Worthington, J., McKeown, S. R., and Hirst, D. G. (2005) Radiogenic therapy: Novel approaches for enhancing tumor radiosensitivity. Technol. Cancer Res. Treat. 4, 343-361.
28. Wilson, W. R., Hicks, K. O., Pullen, S. M., Ferry, D. M., Helsby, N. A., and Patterson, A. V. (2007) Bystander effects of bioreductive drugs: Potential for exploiting pathological tumor hypoxia with dinitrobenzamide mustards. Radiat. Res. 167, 625-636.
29. Denny, W. A., and Wilson, W. R. (1998) The design of selectively activated anti-cancer prodrugs for use in antibody-directed and gene-directed enzyme-prodrug therapies. J. Pharm. Pharmacol. 50, 387-394.
30. Knox, R. J., Boland, M. P., Friedlos, F., Coles, B., Southan, C., and Roberts, J. J. (1988) The nitroreductase enzyme in Walker cells that activates 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) to 5-(aziridin-1-yl)-4- hydroxylamino-2-nitrobenzamide is a form of NAD(P)H dehydrogenase (quinone) (EC 1.6.99.2). Biochem. Pharmacol. 37, 4671-4677.
31. Knox, R. J., Friedlos, F., Sherwood, R. F., Melton, R. G., and Anlezark, G. M. (1992) The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954). A comparison of an Escherichia coli nitroreductase and Walker DT diaphorase. Biochem. Pharmacol. 44, 2297-2301.
32. Knox, R. J., Jenkins, T. C., Hobbs, S. M., Chen, S., Melton, R. G., and Burke, P. J. (2000) Bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) by human NAD(P)H quinone oxidoreductase 2: A novel co-substrate mediated antitumor prodrug therapy. Cancer Res. 60, 4179-4186.
33. Chen, M. J., Chun-Faye, G. A., Searle, P. F., Young, L. S., and Kerr, D. J. (2001) Gene therapy for colorectal cancer: Therapeutic potential. Biodrugs 15, 357-367.
34. Tang, M. H. Y., Helsby, N. A., Wilson, W. R., and Tingle, M. D. (2005) Aerobic 2- and 4-nitroreduction of CB1954 by human liver. Toxicology 216, 129-139.
35. Huen Yin Tang, M., Helsby, N. A., Goldthorpe, M. A., Thompson, K. M., Al-Ali, S., and Tingle, M. D. (2007) Hepatic nitroreduction, toxicity and toxicokinetics of the anti-tumour prodrug CB1954 in mouse and rat. Toxicology 240, 70-85.
36. Ekmekcioglu, S., Tang, C. H., and Grimm, E. A. (2005) NO news is not necessarily good news in cancer. Curr. Cancer Drug Targets 5, 103-115.
37. Ohta, T., Takahashi, M., and Ochiai, A. (2005) Increased protein expression of both inducible nitric oxide synthase and cyclooxygenase-2 in human colon cancers. Cancer Lett. 239, 246-253.
38. Entwistle, I. D., Gilkerson, T., Johnstone, R. A. W., and Telford, R. P. (1978) Rapid catalytic transfer reduction of aromatic nitro compounds to hydroxylamines. Tetrahedron 34, 213-215.
39. ω- hydroxynor-L-arginine. Biochemistry 37, 10453-10460.
40. Wu, C., Zhang, J., Abu-Soud, H., Ghosh, D. K., and Stuehr, D. J. (1996) High-level expression of mouse inducible nitric oxide synthase in Escherichia coli requires coexpression with calmodulin. Biochem. Biophys. Res. Commun. 222, 439-444.
41. Ghosh, S., Gachhui, R., Crooks, C., Wu, C., Lisanti, M. P., and Stuehr, D. J. (1998) Interaction between caveolin-1 and the reductase domain of endothelial nitric oxide synthase. J. Biol. Chem. 273, 22267-22271.
42. Abu-Soud, H. M., Gachhui, R., Raushel, F. M., and Stuehr, D. J. (1997) The ferrous-dioxy complex of neuronal nitric oxide synthase. Divergent effects of L-arginine and tetrahydrobiopterin on its stability. J. Biol. Chem. 272, 17349-17353.
43. Bradford, M. M. (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72, 248-252.
44. Bredt, D. S., and Snyder, S. H. (1990) Isolation of nitric oxide synthetase, a calmodulin-requiring enzyme. Proc. Natl. Acad. Sci. U.S.A. 87, 682-685.
45. Crow, J. P. (1997) Dichlorodihydrofluorescein and dihydrorhodamine 123 are senitive indicators of peroxynitrite in vitro: Implications for intracellular measurements of reactive nitrogen and oxygen species. Nitric Oxide: Biol. Chem. 1, 145-157.
46. McMillan, K., and Masters, B. S. (1993) Optical difference spectrophotometry as a probe of rat brain nitric oxide synthase heme-substrate interaction. Biochemistry 32, 9875-9880.
47. Workman, P. (1992) Bioreductive mechanisms. Int. J. Radiat. Oncol. Biol. Phys. 22, 631-637.
48. Mason, R. P., and Holtzman, J. L. (1975) The mechanism of microsomal and mitochondrial nitroreductase. Electron spin resonance evidence for nitroaromatic free radical intermediates. Biochemistry 14, 1626-1632.
49. Santolini, J., Adak, S., Curran, C. M. L., and Stuehr, D. J. (2001) A kinetic simulation model that describes catalysis and regulation in nitric oxide synthase. J. Biol. Chem. 276, 1233-1243.
50. Zhang, J., Martasek, P., Paschke, R., Shea, T., Masters, B. S., and Kim, J. J. P. (2001) Crystal structure of the FAD/NADPH-binding domain of rat neuronal nitric oxide synthase. J. Biol. Chem. 276, 37506-37513.
51. Garcin, E. D., Bruns, C. M., Lloyd, S. J., Hosfield, D. J., Tiso, M., Gachhui, R., Stuehr, D. J., Tainer, J. A., and Getzoff, E. D. (2004) Structural basis for isozyme-specific regulation of electron transfer in nitric oxide synthase. J. Biol. Chem. 279, 37918-37927.
52. Johansson, E., Parkinson, G. N., Denny, W. A., and Neidle, S. (2003) Studies on the nitroreductase prodrug-activating system. Crystal structures of complexes with the inhibitor dicoumarol and dinitrobenzamide prodrugs and of the enzyme active form. J. Med. Chem. 46, 4009-4020.
53. Walton, M. I., Wolf, C. R., and Workman, P. (1989) Molecular enzymology of the reductive bioactivation of hypoxic cell cytotoxins. Int. J. Radiat. Oncol. Biol. Phys. 16, 983-986.
54. Miller, R. T., Martasek, P., Omura, T., and Masters, B. S. S. (1999) Rapid kinetic studies of electron transfer in the three isoforms of nitric oxide synthase. Biochem. Biophys. Res. Commun. 265, 184-188.